Your browser doesn't support javascript.
loading
Reactogenicity, safety, and immunogenicity of chimeric haemagglutinin influenza split-virion vaccines, adjuvanted with AS01 or AS03 or non-adjuvanted: a phase 1-2 randomised controlled trial.
Folschweiller, Nicolas; Vanden Abeele, Carline; Chu, Laurence; Van Damme, Pierre; García-Sastre, Adolfo; Krammer, Florian; Nachbagauer, Raffael; Palese, Peter; Solórzano, Alicia; Bi, Dan; David, Marie-Pierre; Friel, Damien; Innis, Bruce L; Koch, Juliane; Mallett, Corey P; Rouxel, Ronan Nicolas; Salaun, Bruno; Vantomme, Valerie; Verheust, Céline; Struyf, Frank.
Afiliación
  • Folschweiller N; GSK, Wavre, Belgium; Takeda Pharmaceuticals, Zurich, Switzerland. Electronic address: nicolas.folschweiller@takeda.com.
  • Vanden Abeele C; GSK, Wavre, Belgium.
  • Chu L; Benchmark Research, Austin, TX, USA.
  • Van Damme P; University of Antwerp, Centre for the Evaluation of Vaccination, Antwerp, Belgium.
  • García-Sastre A; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pa
  • Krammer F; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Nachbagauer R; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Moderna, Cambridge, MA, USA.
  • Palese P; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Solórzano A; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Pfizer, Pearl River, NY, USA.
  • Bi D; GSK, Wavre, Belgium.
  • David MP; GSK, Wavre, Belgium.
  • Friel D; GSK, Wavre, Belgium.
  • Innis BL; GSK, King of Prussia, PA, USA; PATH, Washington, DC, USA.
  • Koch J; GSK, Wavre, Belgium; UCB, Brussels, Belgium.
  • Mallett CP; GSK, Rockville, MD, USA.
  • Rouxel RN; GSK, Rixensart, Belgium; MSD Animal Health, Bergen, Norway.
  • Salaun B; GSK, Rixensart, Belgium.
  • Vantomme V; GSK, Wavre, Belgium.
  • Verheust C; GSK, Wavre, Belgium.
  • Struyf F; GSK, Wavre, Belgium; Janssen Research and Development, Beerse, Belgium.
Lancet Infect Dis ; 22(7): 1062-1075, 2022 07.
Article en En | MEDLINE | ID: mdl-35461522
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Adult / Humans Idioma: En Revista: Lancet Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Vacunas contra la Influenza / Gripe Humana Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies Límite: Adult / Humans Idioma: En Revista: Lancet Infect Dis Asunto de la revista: DOENCAS TRANSMISSIVEIS Año: 2022 Tipo del documento: Article